Fecal Microbiota Transplantation

An FDA advisory committee recently voted there was adequate data to support the safety and efficacy of fecal microbiota transplant therapy Rebyota for the treatment of adult patients with recurrent Clostridioides difficile infection.

PHOENIX — A fecal microbiota transplant from healthy donors enabled patients with severe peanut allergy to safely eat small amounts of peanut, according to a presentation at American Academy of Allergy, Asthma & Immunology Annual Meeting.

Among patients with ulcerative colitis, fecal microbiota transplantation with super donor stool was not superior to autologous stool in inducing remission, according to study results.

Oral lyophilized fecal microbiota transplantation following antibiotic use induced and maintained remission in patients with active ulcerative colitis, according to research published in Lancet Gastroenterology and Hepatology.

Improvements in intrahepatic and circulatory inflammation markers were observed after fecal microbiota transplantation in patients with severe alcohol associated hepatitis, according to a presenter at The Liver Meeting Digital Experience.

In this video, Paul Feuerstadt, MD, FACG, AGAF, spoke about new changes to the American College of Gastroenterology’s guidelines on Clostridioides difficile infection treatment, which were discussed at the ACG Annual Scientific Meeting.

LAS VEGAS — Fecal microbiota transplant capsules may improve cognition in patients with hepatic encephalopathy; however, results may vary by donor and recipient factors, according to a presentation at the ACG Annual Scientific Meeting. “FMT is likely safe with rigorous screening protocol, though some patient subgroups with very advanced cirrhosis and decompensated disease potentially warrant exclusion of this treatment,” Patricia P. Bloom, MD, transplant hepatologist from the University of Michigan, said during the presentation. “It is possible reversing rifaximin (Xifaxan, Salix Pharmaceuticals) resistance is another mechanism by which FMT is effective in this condition.”

Mixed-donor nonintensive fecal microbiota transplantation induced significant weight loss in certain people with obesity as well as more effectively increased butyrate-producing bacteria than single-donor intensive transplantation.

Researchers discovered a group of bacterial species and strains that may be used as an alternative to fecal microbiota transplantation to restore a patient’s gut microbiome, according to a study in Nature Microbiology.

Fecal microbiota transplantation is not yet FDA approved for treating recurrent Clostridioides difficile despite several studies showing it to be efficacious and safe.